I recently shared a BMJ report that outlined the approval of Esketamine in Europe:
Since sharing this news, the following rapid response by the MHRA [The Medicines and Healthcare products Regulatory Agency] has been published in the BMJ:
The lead signatory to the Letter mentioned in the original BMJ article has outlined a different narrative [as published in the BMJ]:
